Pegylated liposomal doxorubicin HCl (Lipo-doxo) is one of the leading approved nanoparticle chemotherapeutic drugs widely used to treat variety of cancers and has demonstrated the most significant reduction in risk for cardiotoxicty compared to non-liposomal, conventional doxorubicin. Despite the fact that Lipo-doxo may target mitochondria either directly or indirectly, few data are available regarding cellular bioenergetics on the regulation of mitochondrial fission and fusion genes. In this work, C2C12 myoblast cells have been used as an in-vitro model to study cellular bioenergetics, variations in gene expressions, and biochemical alterations induced by Lipo-doxo under high glucose (25 mM) and normal glucose (5.5 mM) conditions. In C2C12 myoblast cells, Lipo-doxo treatment significantly reduced both mitochondrial oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) under both glucose conditions in a dose dependent manner. Furthermore, Lipo-doxo treatment dysregulated the expression of mitochondrial fission and fusion genes. This dysregulation of mitochondrial fission and fusion genes may influence transformation of the network's connectivity. Using confocal microscopy of C2C12 myoblast cells, we showed that treatment of C2C12 cells with 30 µg/mL Lipo-doxo under high glucose and normal glucose conditions, induced cellular defects. This study provided a better characterization of the effect of Lipo-doxo induced cardiotoxicity.

The aim of this study is to perform molecular docking studies to identify potential binding affinities of the phyto-compounds from compounds claulamines E, clausemarin B, Clausenaline C, Clausenaline E, Murrayanine, vanillic acid, Xanthotoxol for searching of lead molecule for anti-diabetic activity.
Computer assisted drug design approach has contributed to successfully disclosure of against diabetic agent. Molecular docking keeps on being a great promise in the field of computer based drug design.
The procedure of molecular docking includes investigation of various holding methods of one ligand with targeted receptors protein. We have found that numerous values of Molecular docking score by Schrodinger. Compounds claulamines E, clausemarin B, Clausenaline C, Clausenaline E, Murrayanine, vanillic acid, Xanthotoxol respectively. Among all the compounds Clausenaline E showed the best docking score. So from this investigation we can say that this compound Clausenaline E can be suggested for further experiment for the grater pharmacological effect in diabetic patient.

The aim of this study is to performed molecular docking studies to identify potential binding affinities of the phytocompounds from compounds Piperine, Piperlonguminine, β-sitosterol. N-isobutyl deca-Qtrans-2-trans-4-dienamide for searching of lead molecule for thrombolytic activity. Docking can be utilized to perform virtual screening on expansive libraries of mixes, rank the outcomes, and propose auxiliary speculations of how the ligands restrain the objective, which is significant in lead advancement. We used molecular docking method to interact the small molecules of given compounds and a protein at the atomic level, which allow us to characterize the behavior of compounds in the binding site of target proteins as well as to evaluate its activity on the target site. A wide range of docking score found during molecular docking by Schrodinger. Compounds Piperine, Piperlonguminine, and β-sitosterol. N-isobutyl deca-trans-2-trans-4-dienamide showed the docking 4.607, 4.459, 3.152, and 1.088 respectively. Among all the compounds Pipeline showed the best docking score. So, Piperine is the best compounds for thrombolytic activity, as it possessed the best value in Molecular docking. Further in vivo investigation need to identify the thrombolytic activity of isolated compounds from Piper-sylvaticum.

Objective: To evaluate the efficacy of adalimumab (ADA) on enthesitis and dactylitis in psoriatic arthritis (PsA), and to assess the prognostic role of dactylitis and enthesitis as expressed by the correlation with remission and low disease activity (LDA) achieving.
Methods: Retrospective, 10-year, observational study of 273 consecutive patients with PsA treated with ADA, 40 mg/every other week, combined with methotrexate in 123 (45.5%) or in monotherapy in 150 (54.95%). ADA was administered as first- or second-line therapy in 200 (73.3%) and 73 (26.7%) patients, respectively. Primary outcome measures: intention to treat analysis of the number of clinically detectable enthesitis in any site according to Leeds Enthesitis Index (LEI), and the number of any digit with dactylitis (0 to 20) at the end of follow-up. Secondary outcome measure: the correlation between the occurrence of dactylitis and enthesitis and remission and MDA.
Results: At baseline, dactylitis and enthesitis were present in 88 (32.2%) and 127 (46.7%) patients, respectively. Dactylitis resolution was recorded in 86,2% patients (p<0.001) and enthesitis in 83.3%, (p<0.001 ), with LEI change from 2.9 ± 1.2 to 0.20 ± 0.3 (p< 0.001). Patients with dactylitis and enthesitis were more likely not to achieve the remission or LDA (adjusted OR of 2.02; 95% CI 1.56-4, 11; p= 0.039 for dactylitis, and 1.88; 95% CI 1.51-4.34; p= 0.039 for enthesitis). No significant differences of efficacy between ADA first-line and second-line and between ADA mono- or combo-therapy groups resulted.
Conclusion: ADA efficacy resulted comparable with other anti-TNF- and non-anti-TNF targeted biologics. Dactylitis and enthesitis represented poor prognostic markers.

Venomous snakes of the genus Gloydius are distributed in eastern Asia. Bites from one species, known as Japanese Mamushi, Gloydius Blomhoffii, are common in Japan. Some patients develop severe symptom, represented by rhabdomyolysis and acute renal failure, and in extreme cases, death has resulted mainly due to intestinal bleeding/necrosis and perforating peritonitis. The mortality rate is estimated to be about 1 death/300 bites. The lethal cases presented with severe abdominal symptoms, including melena and ileus, and the severe cases including the lethal cases present with higher creatinine kinase values and white blood cell counts. Therefore, it was found that these are reliable indicators predicting the severity of envenomation. The severe and non-severe cases can often be distinguished by the rate of elevation of these laboratory values. At present, mamushi-specific antivenom is recognized as the sole effective medicine against a mamushi bite; however, the clinical results might fail to meet expectations. In this review, we discuss problems associated with treating cases of mamushi bite, our recent trials, and perspectives regarding solutions to the clinical problems encountered.